Systemic administration of baclofen and the GABA sub(B) antagonist, CGP 35348, does not affect GABA, glutamate or aspartate in microdialysates of the striatum of conscious rats

Neither (-)-baclofen, administered systemically at a dose of 20 mg/kg i.p., nor the GABA sub(B) antagonist, CGP 35348 (300 mg/kg i.p.) had significant effects on basel overflow of GABA, glutamate, or aspartate nor on that evoked by 100 mmol/l K super(+) in the striatum of the conscious, freely movin...

Full description

Saved in:
Bibliographic Details
Published in:Naunyn-Schmiedeberg's archives of pharmacology 1992-01, Vol.345 (5), p.548-552
Main Authors: Waldmeier, P C, Stoecklin, K, Feldtrauer, J-J
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Neither (-)-baclofen, administered systemically at a dose of 20 mg/kg i.p., nor the GABA sub(B) antagonist, CGP 35348 (300 mg/kg i.p.) had significant effects on basel overflow of GABA, glutamate, or aspartate nor on that evoked by 100 mmol/l K super(+) in the striatum of the conscious, freely moving rat. To ascertain this result, (-)-baclofen was also administered between two K super(+) stimulations, so that the first stimulation could serve as an intraindividual control of the second. The compound did not significantly affect K super(+) evoked overflow of any of the three transmitter amino acids under these conditions. It must be emphasized that these data do not exclude the operativity of presynaptic GABA sub(B) auto- and hetero-receptors in vivo. They only suggest that this question must, in all probability, be addressed by other techniques than brain dialysis.
ISSN:0028-1298